Open Access

Capreomycin is active against non-replicating M. tuberculosis

Annals of Clinical Microbiology and Antimicrobials20054:6

https://doi.org/10.1186/1476-0711-4-6

Received: 01 February 2005

Accepted: 01 April 2005

Published: 01 April 2005

Abstract

Background

Latent tuberculosis infection (LTBI) is affecting one-third of the world population, and activation of LTBI is a substantial source of new cases of tuberculosis. LTBI is caused by tubercle bacilli in a state of non-replicating persistence (NRP), and the goal of this study was to evaluate the activity in vitro of various antimicrobial agents against non-replicating M. tuberculosis.

Methods

To achieve a state of NRP we placed broth cultures of M. tuberculosis (three strains) in anaerobic conditions, and in this model tested all known anti-TB drugs and some other antimicrobial agents (a total of 32 drugs). The potential effect was evaluated by plating samples from broth cultures for determining the number of viable bacteria (CFU/ml) during a prolonged period of cultivation. Besides drug-free controls we used metronidazole for positive controls, the only drug known so far to be effective against tubercle bacilli in anaerobic setting.

Results

On a background of non-replicating conditions in drug-free cultures and clear bactericidal effect of metronidazole none of the antimicrobial agents tested produced effect similar to that of metronidazole except capreomycin, which was as bactericidal at the same level as metronidazole.

Conclusion

The unique ability of capreomycin to be bactericidal in vitro among the anti-TB drugs against non-replicating tubercle bacilli may justify the search for other drugs among peptide antibiotics with similar activity. This phenomenon requires further studies on the mechanism of action of capreomycin, and evaluation of its activity in appropriate animal models.

Keywords

latent tuberculosis infection dormant tubercle bacilli capreomycin

Background

Latent tuberculosis infection (LTBI) is defined as a clinical condition without clinical or radiological signs of active disease, and it is manifested only by a positive tuberculin skin test [1]. Approximately two billion people, or one-third of the world's population, have LTBI, and approximately 10% of them will develop active TB during their lifetime. It is also estimated that one-third of all new cases of active TB (about 2.5 million cases reported annually in the world), results from activation of LTBI. The role of LTBI is even greater in persons co-infected with HIV. Currently, 11 million people in this category are registered throughout the world, and at least 10% of them develop active TB every year. All these facts have placed the problem of diagnosis and effective treatment of LTBI in the frontier of current TB research agenda.

There is plenty of evidence that the basis for LTBI in humans is persistence of tubercle bacilli in vivo for long periods of time. This status is currently defined as dormancy or non-replicating persistence (NRP) emphasizing that each of these terms is only descriptive, regardless of the mechanisms involved [2]. An important element of this definition is that the suggested terms indicate not only the constant number of tubercle bacilli over time (stationary phase of growth in vitro), but actual lack of multiplication. Besides LTBI, a part of bacterial population in patients with active disease also persists in a non-replicating state, and there is an obvious need for a drug affecting this sub-population – a drug that would be considered for incorporation into treatment regimens.

The in vivo factors that may induce NRP include depletion of nutrients, shifts in pH, accumulation of growth inhibiting products, and depletion of oxygen. Discovery of effective drugs against non-replicating tubercle bacilli requires appropriate in vitro models of dormancy. In the past, the following in vitro models were suggested: cultivation at 8°C for 31 days [3], nutrient depletion [4], depletion of oxygen in vigorously shaken broth cultures [5], anaerobic model in submerged broth cultures [6], and cultivation at pH 4.8–5.0 in broth for six weeks [7]. Not all of these models fully comply with the above definition of dormancy, and the most popular among them became the anaerobic model by Wayne [6]. The physiological parameters of NRP of M. tuberculosis in this model were studied intensively [812], which makes the anaerobic conditions the most attractive tool for further studies of NRP.

The aim of this study was to analyze the activity of all available anti-tuberculosis drugs in broth cultures in in vitro anaerobic conditions. Only capreomycin was found to be bactericidal in these conditions, and the activity of this drug was at the same level as that of metronidazole.

Methods

Antimicrobial agents

Metronidazole was obtained from Searle (Skokie, IL). All other drugs and reagents were obtained from Sigma (St. Louis, MO). Stock solutions of rifampin were made in methanol, ethionamide – in DMSO, and all other drugs – in distilled water. Working solutions were prepared from stock solution in 7H9 broth.

Test-strains

Three drug-susceptible strains of M. tuberculosis, H37Rv, Erdmann, and Atencio, were kept in aliquots of 7H9 broth culture frozen at -70°C. The inocula were prepared by 5–7 days of sub-cultivation in fresh 7H9 broth tubes (4.5 ml) placed in a roller drum for better aeration. These cultures were used as inocula when the turbidity became equal to the optical McFarland standard #1, which corresponded to about 108 CFU/ml.

Inoculum for hypoxia in vitro model

The so-called "anaerobic inoculum" of tubercle bacilli was prepared according to the original description [6, 13]. According to these reports, with conditions of gradually decreased supply of oxygen, the tubercle bacilli undergo an orderly metabolic down-shift into a state of dormancy when the bacteria accumulate in the bottom of the unshaken tubes (20 × 125 mm) containing 10 ml of broth. In our experiments, a bacterial suspension (optical density at #1 McFarland standard) was made from 10–14 day-old 7H11 agar culture. After homogenization with glass beads, the suspension was placed into 25 × 125 mm tubes, 4 ml in each, and an additional 6.0 ml of fresh 7H9 broth was added. After cultivation at 37°C for 19 days in an undisturbed upright position, the caps were loosened by 1/2 turn, and the tubes were placed into an anaerobic jar for another nine days of cultivation. The jars contained indicator strips and GasPackPlus envelopes filled with 10 ml of sterile water. Sediments were removed from tubes by inserting pipettes through supernatants, and then combined into one tube, approximately 8 ml from each four tubes set.

Medium for anaerobic cultivation

Standard 7H12 broth in 12B Bactec vials (4.0 ml) was supplemented with three aqueous filter-sterilized reagent solutions, each added in a volume of 0.1 ml per vial. Two of them were oxygen-reducing reagents: Sodium thioglycolate and L-cysteine hydrochlorate. The third was methylene blue, a color indicator of oxygen presence. The final concentration was 0.5 mg/ml of each of these reagents in the medium.

Hypoxia in vitro model: experiments with drugs

We used the Bactec-460 system set in an anaerobic mode for testing activity of drugs in anaerobic conditions. After addition of the above-described reagents, the bottom edges of the caps of the12B vials were sealed by coating with rubber cement, the drug solutions were added (0.1 ml per 4.0-ml vial), and the vials were run through the Bactec machine with an anaerobic setting using Nitrogen gas + 5% CO2. The vials were inoculated with the described above bacterial suspension (0.1 ml per vial). The vials were subsequently incubated at 37°C, and checked daily for a possible change in color. Those with blue color (disruption of anaerobic conditions) were discarded. The vials were run through the anaerobic Bactec-460 system every four days to record the cumulative Growth Index (GI). To determine the number of viable bacteria in these cultures, we took samples from alternate vials, starting at day zero, and subsequently every week, for plating appropriate dilutions on 7H11 agar plates. The results were expressed in CFU/ml at each time-point.

Statistical analyses

We have determined the regression coefficients for each of the curves of decline in bacterial counts (CFU/ml) in the presence of all drugs, as well as in the drug-free controls. For each coefficient we determined confidence limits for the 0.95 probability, as well as its level of statistical significance (difference from the "no-decline") expressed in the p value. In addition, we determined the statistical difference between the regression coefficients for each drug, on one hand, and the same values found for drug-free controls, also expressed as a p value.

Results

Model validation

We evaluated the kinetics of GI and CFU/ml in three preliminary experiments (with three strains) using vials without any drugs added and in the presence of metronidazole. Cultivation in these preliminary experiments continued up to 29 days, and samples for CFU/ml determination were taken from alternate vials on days 0, 4, 8, 11, 15, 18, 22, 25, and 29. During this period of time, production of CO2 in cultures remained at a steady low level (with daily GIs less than 10), when cumulative four-day readings on the Bactec-460 machine did not exceed GI = 40. The number of CFU/ml in drug-free vials remained relatively steady during this period, with only a small decline within the first 18 days. The kinetics of CFU/ml in vials containing metranidazole was different: a decline could have been detected at day 8, but it became more evident (by one-to-two log10) at day 15. This decline in the number of CFU/ml was more significant in the presence of 32 μg/ml of metronidazole than at 8.0 μg/ml. This difference compared to the drug-free medium and between the effects of two drug concentrations became greater during the subsequent period. Nevertheless, we found these differences within the first 15 days of cultivation quite sufficient and less laborious for the subsequent 15 validation experiments (five with each of the test-strains), in which the number of CFU/ml was determined on days 0, 8, and 15. In addition, we incorporated two more agents along with metronidazole (rifampin 0.5 μg/ml and isoniazid 0.5 μg/ml) into these experiments. The summary of these experiments, presented in Table 1, demonstrated results similar to that in the original report regarding activity of these agents in anaerobic conditions (13): clear dose-dependent bactericidal effect of metronidazole, very slight effect of rifampin, and no effect of isoniazid. The results of one of these experiments is also shown in Fig. 1.
Table 1

Antimicrobial Effect of Metronidazole (Met), Rifampin (RMP) and Isoniazid (INH)Against Three Strains of M. tuberculosis

Drug/ Conc. (μg/ml)

Log10 of CFU/ml on days 0, 8 and 15

 

H37Rv

Atencio

Erdman

 

0

8

15

0

8

15

0

8

15

Control

6.76

6.30

6.04

7.26

7.49

7.34

7.08

6.63

6.30

Met. 32.0

6.76

5.18

4.20

7.26

5.73

5.76

7.08

4.70

4.18

Met. 8.0

6.76

5.70

5.72

7.26

6.49

6.20

7.08

5.88

5.18

RMP 0.5

6.76

6.11

5.91

7.26

6.50

6.50

7.08

5.76

5.59

INH 0.5

6.76

6.00

5.30

7.26

7.00

7.00

7.08

6.00

5.87

Figure 1

One of experiments confirming the validity of the anaerobic model: kinetics of CFU/ml of M. tuberculosis on days 0, 8, and 15 in 7H12 broth in anaerobic conditions: in drug-free control, in the presence of metronidazole (Met, 32 and 8 μg/ml), rifampin (RMP, 0.5 μg/ml), and isoniazid (INH, 0.5 μg/ml).

Screening of other drugs

In subsequent experiments, each drug was tested in three concentrations (μg/ml): amikacin (8, 4, 2), capreomycin (8, 4, 2), ciprofloxacin (4, 2, 1), clarithromycin (32, 8, 2), ethambutol (8, 4, 2), ethionamide (4, 2, 1), gatifloxacin (2, 0.5, 0.12), isoniazid (2.5, 0.5, 0.1), levofloxacin (2, 1, 0.5), PAS (25 and 6.25), pyrazinamide at pH 6.0 (900, 300, 100), morphazinamide (300 and 100), rifabutin (0.5, 0.25, 0.12), rifampin (0.5, 0.25, 0.12), rifapentine (0.12, 0.06, 0.03), streptomycin (8, 4, 2), sparfloxacin (2, 1, 0.5), thiacetazone (1.2, 0.3, 0.075). Other drugs were tested in single concentrations: amoxicillin, augmentin, clindomycin, ceftriaxone, dapsone, doxycycline, erythromycin, cefoxitin, gentamycin, imipenem, minocycline, pristomycin, sulfamethoxazole, tetracycline, trimethoprim. Each experiment for testing two or three of the above listed drugs always included a drug-free control and metronidazole. The analyses included only those experiments in which clear difference in the kinetics of CFU/ml between drug-free controls and metronidazole have been observed.

Other criteria for inclusion were: no appearance of blue color in the media, and no greater than GI = 50 cumulative readings at days 7–8, 14–15, and 21. These screening experiments clearly demonstrated that none of the above listed agents, except capreomycin (see below), could produce any antimicrobial activity in the model used, contrasting with clear bactericidal activity of metronidazole. The results of some of these experiments are shown in Table 2 and Fig. 2.
Table 2

Kinetics of the Number of Viable Bacteria (Log10 CFU/ml). Initial CFU/ml Contents: H37Rv – 6.32, Atencio – 6.75, Erdman – 6.52.

Drug/ Conc. (μg/ml)

Log10 of CFU/ml on days 7, 14 and 21

 

H37Rv

Atencio

Erdman

 

7

14

21

7

14

21

7

14

21

Control

6.04

5.49

4.91

5.30

5.62

4.86

5.90

5.32

4.91

MET, 16

4.43

4.46

3.12

4.54

3.84

3.15

4.04

3.67

3.28

EMB, 8

5.86

5.39

4.91

6.17

5.30

4.71

5.82

5.28

4.72

SM, 8

6.06

5.12

4.67

6.07

5.20

4.31

5.75

5.16

4.46

PZA, 900*

5.96

5.23

4.45

5.96

5.08

4.16

5.59

5.17

4.50

*At pH 6.2

Figure 2

Kinetics of CFU/ml of M. tuberculosis in anaerobic conditions on days 0, 7, 14, and 21 in one of experiments with conventional anti-TB drugs compared to that of the drug-free control and effect of metronidazole (Met. 16 μg/ml): ethambutol (EMB, 8 μg/ml), streptomycin (SM, 8 μg/ml), and pyrazinamide (PZA, 900 μg/ml, at pH 6.0).

Activity of capreomycin in anaerobic cultures

A series of 29 experiments (six of which included capreomycin) were conducted with assessment of the number of CFU/ml at four time-points: days 0, 7, 14, and 21. Some decline in the number of viable bacteria, at one log10 or less, occurred in drug-free controls during this period. Metronidazole used in a concentration of 16 μg/ml in these experiments produced a more significant effect, with a difference of 1–2 log10 or more compared with the number of CFU/ml in drug-free controls at day 21 of cultivation (Table 3). The effect of capreomycin at a concentration of 8.0 μg/ml in these experiments was similar to that of metronidazole, and clear dose-response relations was seen for this effect (Table 3 and Fig. 3).
Table 3

Antimicrobial Effect of Capreomycin (CM) at Concentrations of 8, 4, and 2 μg/ml Initial CFU/ml Content: H37Rv – 7.28, Atencio – 6.31, Erdman – 6.88

Drug. Conc.

Log10 of CFU/ml on days 7, 14 and 21

 

H37Rv

Atencio

Erdman

 

7

14

21

7

14

21

7

14

21

Control

6.54

5.85

5.80

6.25

6.30

4.92

6.78

5.20

5.31

MET, 16

5.29

4.71

3.28

5.37

6.54

3.82

6.08

5.00

3.88

CM, 8

5.72

4.57

3.13

5.56

5.97

3.24

5.68

4.88

3.18

CM, 4

5.85

4.83

3.79

5.60

6.13

3.36

5.65

5.02

3.93

CM, 2

6.17

4.82

3.88

5.83

6.26

 

5.62

 

4.71

Figure 3

Effect of capreomycin (CM, at 8, 4, and 2 μg/ml) in one of experiments against M. tuberculosis (H37Rv) in anaerobic conditions compared to that of metronidazole (Met, 16 μg/ml)

Statistical significance

Decline in the number of viable bacteria in drug-free controls was not significant, with the exception being for the strain Erdman in experiments presented in Table 1 and 2 (p < 0.05). Decline in the number of viable bacteria in the presence of RMP and INH (Table 1) and EMB and SM (Table 2) was not significant in experiments with strains H37Rv and Atencio (p > 0.05). Decline in CFU/ml in the presence of metranidazole 32.0 and 16.0 μg/ml was statistically significant (p < 0.05) in all experiments, with best results in experiments with the H37Rv strain, showing most significant difference from decline in controls. Capreomycin (Table 3) was most active against strain H37Rv at concentrations of 8.0 and 4.0 μg/ml (p = 0.002 and p = 0.004, correspondingly) with definitive difference from the curve of decline in the control (p = 0.003 and p = 0.009, correspondingly).

Discussion

We examined the antimicrobial activity of all anti-TB drugs and of other antimicrobial agents against M. tuberculosis in anaerobic conditions. For this purpose, we used an anaerobic in vitro model based on the same principles suggested by Wayne for submerged broth culture cultivation (6,13). Preparation of the "anaerobic inoculum" of M. tuberculosis was identical to the procedure described in these reports. On the other hand, to evaluate the activity of various drugs, we used a different technology (the Bactec-460 system) for subsequent cultivation in anaerobic conditions. One of the advantages of this system is that it is less laborious for testing a large number of drugs than the original technique. Running the culture vials through the Bactec-460 anaerobic system with a nitrogen gas flow effectively provided anaerobic conditions, enforced by oxygen-reducing agents and controlled by the color indicator present in each vial. In the past, it was established that daily release of CO2, which was automatically recorded in this system as radiometric Growth Index (daily GI), correlates well with the increase in the number of viable bacteria. Therefore, detection of any significant amount of CO2 released in cultures in any of the vials provided an instant indication of possible growth, and such vials could have been immediately removed from the experiment. The validity of this system was confirmed in a series of experiments to test the activity of metronidazole, rifampin, and isoniazid. Results obtained in these experiments were identical to those reported by Wayne and Sramek [13].

Among all drugs listed in the Methods section, only capreomycin exhibited a clear bactericidal effect similar to that of metronidazole against non-replicating M. tuberculosis in anaerobic conditions, and this finding was confirmed in six experiments with three M. tuberculosis strains.

We previously reported that the MICs of capreomycin in aerobic conditions against actively multiplying M. tuberculosis were within the range of 1.25–2.5 μg/ml in either liquid or solid (7H11 agar) medium, and the MBC/MIC ratio was equal to 2, similar to that of streptomycin, amikacin, and kanamycin [14, 15]. New findings that capreomycin can be active against non-replicating M. tuberculosis require further investigation, particularly in appropriate animal models. The unusual phenomenon of such activity also requires further studies in regard to the mode of action of this drug in anaerobic conditions. It is well known that M. tuberculosis in NRP state represent a problem of LTBI, but also can be a part of the bacterial population in new patients with active tuberculosis [16]. Therefore, it is quite possible that capreomycin may not only be effective in patients with LTBI, but also may play an important role as an element of an initial treatment regimen in new patients with active tuberculosis. Either of these possibilities should be investigated in various animal models and subsequently considered for confirmation in clinical trials. Setting up and conducting a large-scale trial with LTBI patients would require a substantial period of observation and can be quite expensive. Therefore, before addressing the issue of treatment of LTBI patients, another option that can be considered is evaluation of the potential effect of capreomycin (in a combination with other drugs) for newly diagnosed patients. This can be achieved in pilot clinical trials using various surrogate markers to determine bactericidal and sterilizing activity of drugs or drug combination [1719]. It is premature to define the exact avenues of clinical studies until the needed information on the effect of capreomycin in appropriate animal models becomes available.

Conclusion

Among the known anti-TB drugs and other tested agents, only capreomycin exhibited a bactericidal effect against non-replicating M. tuberculosis in anaerobic conditions in vitro. Further studies are needed to investigate the mode of action of this drug in such a setting, as well as the efficacy in appropriate animal models, and, perhaps, in pilot clinical trials. Testing in an anaerobic dormancy model of some other polypeptides may lead to the discovery of other drugs effective against non-replicating M. tuberculosis.

Declarations

Acknowledgements

This work was supported by NIH Grant No. U19-AI40917. We thank Andrew J. Kittelson for the statistical analyses of the experimental data.

Authors’ Affiliations

(1)
National Jewish Medical and Research Center
(2)

References

  1. Nuermberger E, Bishai WR, Grosset JH: Latent tuberculosis infection. Sem Resp Crit Care Med. 2004, 25 (3): 317-336. 10.1055/s-2004-829504.View ArticleGoogle Scholar
  2. Wayne LG, Sohaskey CD: Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol. 2001, 55: 139-193. 10.1146/annurev.micro.55.1.139View ArticlePubMedGoogle Scholar
  3. Dickinson JM, Mitchison DA: Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis. 1981, 123: 367-371.PubMedGoogle Scholar
  4. Yuan Y, Crane DD, Barry CE: Stationary phase-associated protein expression of Mycobacterium tuberculosis : function of the mycobacterial alpha-chrystallin homolog. J Bacteriol. 1996, 178: 4484-4492.PubMed CentralPubMedGoogle Scholar
  5. Lyon RH, Lichstein HC, Hall WH: Factors affecting growth of Mycobacterium tuberculosis in aerobic and stationary cultures. Am Rev Respir Dis. 1961, 83: 255-260.PubMedGoogle Scholar
  6. Wayne LG: Dynamics of submerged growth of Mycobacterium tuberculosis under anaerobic and microaerophilic conditions. Am Rev Respir Dis. 1976, 114: 807-811.PubMedGoogle Scholar
  7. Heifets L, Lindholm-Levy P: Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992, 145: 1223-1225.View ArticlePubMedGoogle Scholar
  8. Wayne LG, Lin KY: Glyoxylate metabolism and adaptation of Mycobacterium truberculosis to survival under anaerobic conditions. Infect Immun. 1982, 37: 1042-1049.PubMed CentralPubMedGoogle Scholar
  9. Boon C, Li R, Qi R, Dick T: Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol. 2001, 183: 2672-2676. 10.1128/JB.183.8.2672-2676.2001PubMed CentralView ArticlePubMedGoogle Scholar
  10. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrel MI, Schoolnik GK: Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-chrystallin. Proc Natl Acad Sci USA. 2001, 98: 7534-7539. 10.1073/pnas.121172498PubMed CentralView ArticlePubMedGoogle Scholar
  11. Voskuil MI, Schnappinger D, Visconti KC: Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med. 2003, 198: 705-711. 10.1084/jem.20030205PubMed CentralView ArticlePubMedGoogle Scholar
  12. Park HD, Guinn KM, Harrel MI: Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol. 2003, 48: 833-843. 10.1046/j.1365-2958.2003.03474.xPubMed CentralView ArticlePubMedGoogle Scholar
  13. Wayne LG, Sramek HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1994, 38: 2054-2058.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Heifets L: MIC as a quantitative measurement of susceptibility of M. avium to seven antituberculosis drugs. Antimicrob Agents Chemother. 1988, 32 (8): 1131-1136.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Heifets L, Lindholm-Levy PA: Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against M. avium and M. tuberculosis. Antimicrob Agents Chemother. 1989, 33 (8): 1298-1303.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Mitchison DA: The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985, 66: 219-225. 10.1016/0041-3879(85)90040-6View ArticlePubMedGoogle Scholar
  17. Bridle R, Odhiambo J, Mitchison D: Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med. 2001, 1 (1): 2- 10.1186/1471-2466-1-2View ArticleGoogle Scholar
  18. Jindani A, Dore CJ, Mitchison DA: Bactericidal and sterilizing activities of antituberculosis drugs during first 14 days. Am J Respir Crit Care Med. 2003, 167 (10): 1299-1301. 10.1164/rccm.200210-1125OCView ArticleGoogle Scholar
  19. Gosling RD, Heifets L, Gillespie SH: A multicentre comparison of novel surrogare marker for determining the specific potency of antituberculosis drugs. J Antimicrob Chemother. 2003, 52 (3): 473-476. 10.1093/jac/dkg345View ArticlePubMedGoogle Scholar

Copyright

© Heifets et al; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement